A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned

Najla El Jurdi; Noa G. Holtzman; Rania Hishmeh; Alain Mina; Eduard Schulz; Anita Stokes; Grace Li; Keith T. Schmidt; William D. Figg; Nicholas Micheletti; Jacqueline W. Mays; Edward W. Cowen; Steven Z. Pavletic; Iskra Pusic

Article

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned

British Journal of Haematology

DOI: 10.1111/bjh.20069

2Citations

1Readers

Get full text

Author supplied keywords

Cite

CITATION STYLE

APA

El Jurdi, N., Holtzman, N. G., Hishmeh, R., Mina, A., Schulz, E., Stokes, A., … Pusic, I. (2025, June 1). A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned. British Journal of Haematology. John Wiley and Sons Inc. https://doi.org/10.1111/bjh.20069

A phase 2 study of single agent ibrutinib for first-line treatment of chronic graft-versus-host disease: A new paradigm and lessons learned

Author supplied keywords

Cite

Register to see more suggestions